title: Ramucirumab approved for gastric cancer.
abstract: Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000096662:Ramucirumab